Lead Investigator: Gregory YH Lip, University of Liverpool
Title of Proposal Research: Evaluating the outcomes and characterisation of atrial fibrillation
Vivli Data Request: 7233
Funding Source: None
Potential Conflicts of Interest: Co-Chair for the GLORIA-AF registry.
Summary of the Proposed Research:
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia that is characterised by an irregular heart beat. In 2010, the global prevalence of AF was estimated at 33.5 million. The condition is associated with an increased risk of stroke, heart failure and mortality, and reduced quality of life. Additionally, it poses a significant healthcare economic burden.
Despite years of research, there remains many aspects of AF that are poorly defined, partly due to the complex nature of this disease. There has been much improvement in the care of patients with AF over the past decade. Nonetheless, further progress needs to be met with greater understanding of the condition. Here, we identify several important topics that warrant further investigation and have good potential to enhance direct patient care by improving risk stratification and the choice of treatment in AF.
This research will be conducted using patients with AF from the GLORIA-AF registry.
Requested Studies:
GLORIA – AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III)
Data Contributor: Boehringer Ingelheim
Study ID: NCT01468701
Sponsor ID: 1160.129
GLORIA – AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III – EU/EEA Member States)
Data Contributor: Boehringer Ingelheim
Study ID: NCT01671007
Sponsor ID: 1160.136
GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III-India and Switzerland)
Data Contributor: Boehringer Ingelheim
Study ID: NCT01937377
Sponsor ID: 1160.171